Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?

By Prosper Junior Bakiny – Feb 22, 2026 at 6:30PM ESTKey PointsVertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too difficult to achieve. We’re bullish on these 10 stocks ›NASDAQ: VRTXVertex PharmaceuticalsMarket Cap$121BToday's Changeangle-down(1.63%) $7.63Current Price$476.90Price as of February 20, 2026 at 4:00 PM ETEven a great stock has a ceiling.Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like Vertex Pharmaceuticals (VRTX +1.63%), an otherwise strong market-beater, has delivered over the past 10 years, with its outstanding CAGR of 18.2% during this period. Could the biotech perform even better in the next 10 years, and turn $100,000 into $1 million by 2036? Image source: Getty Images. The challenge A decade ago, Vertex Pharmaceuticals was a much smaller company and was much earlier in its quest to transform the cystic fibrosis (CF) market. It earned approval from the U.S. Food and Drug Administration for Kalydeco, the first medicine to treat the underlying causes of this rare disease, in 2012. Vertex's CF franchise will remain a growth driver for the foreseeable future. There is still a meaningful number of patients to target, and its most important products won't run into patent cliffs until the end of the next decade. But the healthcare leader is now much larger and has a smaller patient population to address. Its CF business alone is unlikely to drive the kind of growth it needs to turn $100,000 into $1 million, or anything close to it, in the next 10 years. ExpandNASDAQ: VRTXVertex PharmaceuticalsToday's Change(1.63%) $7.63Current Price$476.90Key Data PointsMarket Cap$121BDay's Range$465.00 - $479.1252wk Range$362.50 - $519.68Volume1MAvg Vol1.5MGross Margin86.32% Vertex Pharmaceuticals could rely on its pipeline candidates. Two of them, inaxaplin and povetacicept, are aiming to treat the underlying causes of diseases for which there are currently no such medicines. But will that be enough, even if they earn approval? Part of Vertex's success in CF was because no rival developed competing CF medicines. For the company to perform even better than it has since 2016, it would need nearly flawless clinical execution, along with sustained leadership in these markets over the next decade. Is that likely to happen? There is a precedent in the biopharma industry. Eli Lilly's CAGR over the past 10 years has been an outrageous 29.9%, but that came after Lilly developed a compound that, in only its third full year on the market, topped the list of the world's best-selling drugs (and could become the top-selling medicine of all time). Investors shouldn't bet on Vertex accomplishing a feat like that. Vertex's stock is still a buy Even if Vertex Pharmaceuticals can't meet such a lofty goal, there are great reasons to consider the stock. Vertex generates consistent revenue and earnings thanks to its CF products, and new additions, like Journavx for acute pain, will contribute. New approvals will also help boost the company's financial results. Vertex may not achieve a 100% success rate with its late-stage programs, and it might eventually face competition. But unlike 10 years ago, the biotech will have a far more diversified lineup in the future. All those are good reasons to buy and hold the stock through the next decade.Read NextFeb 18, 2026 •By Adria CiminoVertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market CrashFeb 13, 2026 •By James BrumleyWhy CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)Feb 10, 2026 •By Adria Cimino1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never SellFeb 10, 2026 •By James HalleyShould You Buy Vertex Before Feb. 12?Feb 9, 2026 •By Prosper Junior BakinyShould You Buy Vertex Pharmaceuticals Before Feb. 12?Jan 29, 2026 •By Prosper Junior BakinyPrediction: 2026 Will Be the Year of Vertex PharmaceuticalsAbout the AuthorProsper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks.

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.TMFPBakinyStocks MentionedVertex PharmaceuticalsNASDAQ: VRTX$476.72 (+1.59%) $+7.45Eli LillyNYSE: LLY$1008.28 (1.46%) $14.94*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.